The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

Christian Manegold*, Anne-Marie C. Dingemans, Jhanelle E. Gray, Kazuhiko Nakagawa, Marianne Nicolson, Solange Peters, Martin Reck, Yi-Long Wu, Odd Terje Brustugun, Lucio Crino, Enriqueta Felip, Dean Fennell, Pilar Garrido, Rudolf M. Huber, Aurelien Marabelle, Marcin Moniuszko, Francoise Mornex, Silvia Novello, Mauro Papotti, Maurice PerolEgbert F. Smit, Kostas Syrigos, Jan P. van Meerbeeck, Nico van Zandwijk, James Chih-Hsin Yang, Caicun Zhou, Everett Vokes

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)194-207
Number of pages14
JournalJournal of Thoracic Oncology
Volume12
Issue number2
DOIs
Publication statusPublished - Feb 2017

Keywords

  • Antiangiogenesis
  • Combination therapy
  • Immunotherapy
  • NSCLC
  • CELL LUNG-CANCER
  • ENDOTHELIAL GROWTH-FACTOR
  • RANDOMIZED CONTROLLED-TRIAL
  • PHASE-III TRIAL
  • DOUBLE-BLIND
  • PATIENTS PTS
  • METASTATIC MELANOMA
  • BEVACIZUMAB BEV
  • VEGF-A
  • TUMOR MICROENVIRONMENT

Cite this

Manegold, C., Dingemans, A-M. C., Gray, J. E., Nakagawa, K., Nicolson, M., Peters, S., Reck, M., Wu, Y-L., Brustugun, O. T., Crino, L., Felip, E., Fennell, D., Garrido, P., Huber, R. M., Marabelle, A., Moniuszko, M., Mornex, F., Novello, S., Papotti, M., ... Vokes, E. (2017). The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. Journal of Thoracic Oncology, 12(2), 194-207. https://doi.org/10.1016/j.jtho.2016.10.003